arrow
A

Asmita Mishra

H. Lee Moffitt Cancer Center and Research Institute
H指数:23
被引数:2,147

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chronic graft vs. host disease following post-transplant cyclophosphamide (PTCy) based prophylaxis vs. non-PTCy prophylaxis

移植后环磷酰胺(PTCy)为基础的预防措施与非PTCy预防措施后的慢性移植物抗宿主病

2026-07-230
OA
Single center evaluation of a composite risk assessment model to predict non-relapse mortality following allogeneic hematopoietic cell transplantation (HCT)

单中心评估一种复合风险预测模型,用于预测异基因造血细胞移植(HCT)后的非复发死亡率。

2026-04-080
PRE
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes

移植后微小残留病(MRD)通过TP53双测序结合APR-246 + 去氧氟尿苷维持治疗预测预后

2025-11-270
OAAI
CHARM is Prognostic of Geriatric Morbidity and Toxicity after Allogeneic Transplant for Older Adults: BMT CTN 1704 Study

CHARM是老年患者异基因移植后预测老年病发病率和毒性的指标:BMT CTN 1704研究

2025-11-240
OAAI
Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia

肥胖及基于体重的化疗剂量调整对急性髓系白血病异基因造血细胞移植结局的影响

2025-10-200
PRE
Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide

Letermovir可降低接受移植后环磷酰胺治疗的HLA匹配和错配异基因造血细胞移植患者中的巨细胞病毒水平。

2025-07-050
PRE
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia

移植预处理、NPM1突变及FLT3-ITD急性髓系白血病中可测量的微小残留病的影响

2025-07-030
OAAI
Novel composite health assessment risk model for older allogeneic transplant recipients: BMT-CTN 1704

新型复合健康评估风险模型用于老年异基因移植受者:BMT-CTN 1704

2025-03-200
OA
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines

美国老年评估实践:针对接受造血细胞移植或嵌合抗原受体T细胞治疗的老年人——移植与细胞治疗学会老年特别兴趣小组与实践指南委员会医师调查

2025-02-010
PRE
Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes

美法仑剂量联合氟达拉滨影响急性髓系白血病和骨髓增生异常综合征异基因移植后胃肠道毒性和移植物抗宿主病

2024-11-010
PRE
Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide
2024-10-011
PRE
Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation

HHV-6B再激活的单倍体干细胞移植受者的结果

2024-09-260
OAAI
Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations
2024-03-280
OAAI
Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide
2024-02-015
PRE
The Transplantation Ecosystem: A New Concept to Improve Access and Outcomes for Older Allogeneic Hematopoietic Cell Transplantation Patients

移植生态系统: 改善老年异基因造血细胞移植患者的获得和结果的新概念

2023-10-017
OAAI
Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
2022-12-1451
OAAI
A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
2022-01-106
OAAI